유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydraat - carcinoom, niet-kleincellige long - antineoplastische middelen - vizimpro, als monotherapie, is geïndiceerd voor de eerste lijn behandeling van volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (niet-kleincellig longcarcinoom) met epidermale groeifactor receptor (egfr) activeren van mutaties.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukemie, myeloïde, acuut - antineoplastische middelen - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosuppressiva - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoom, niet-kleincellige long - antineoplastische middelen - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische middelen - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

유럽 연합 - 네덜란드어 - EMA (European Medicines Agency)

pfizer limited - insulin human - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - exubera is geïndiceerd voor de behandeling van volwassen patiënten met type 2 diabetes mellitus notadequately bediend met orale antidiabetica en die insuline therapie. exubera is ook geïndiceerd voor de behandeling van volwassen patiënten met type 1 diabetes mellitus, inaddition te lang of intermediair optreedt subcutane insuline, voor wie de potentiële voordelen ofadding insuline voor inhalatie opwegen tegen de mogelijke bezorgdheid over de veiligheid (zie hoofdstuk 4.

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - dinoproston 0,5 mg/3 g - gel voor endocervicaal gebruik - 0,5 mg - 3 g - dinoproston 0.5 mg - dinoprostone

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - dinoproston 0,5 mg - tablet - 0,5 mg - dinoproston 0.5 mg - dinoprostone

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - dinoproston 1 mg/ml - concentraat voor oplossing voor infusie - 0,75 mg - dinoproston 1 mg/ml - dinoprostone

벨기에 - 네덜란드어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - dinoproston 10 mg/ml - concentraat voor oplossing voor infusie - 5 mg - dinoproston 10 mg/ml - dinoprostone